This inventor holds 2 USPTO granted patents and 1 published patent application. Top assignees: University of California, The University of Texas System. Active years: 2012-2013.
Company Filing History:
2 out of 15,988 
1 out of 5,630 
Years Active: 2012-2013
Title: The Innovative Contributions of Wen-Lin Kuo
Introduction
Wen-Lin Kuo is a notable inventor based in San Ramon, CA (US). He has made significant contributions to the field of cancer research, particularly in the development of predictive and therapeutic markers for ovarian cancer. With a total of 2 patents, his work has the potential to impact the diagnosis and treatment of aggressive cancers.
Latest Patents
Wen-Lin Kuo's latest patents focus on two critical areas in cancer research. The first patent addresses predictive and therapeutic markers in ovarian cancer. This research highlights the importance of detecting diseases characterized by increased expression of apoptosis-suppressing genes. Specifically, genes located in human chromosomal regions 8q24, 11q13, and 20q11-q13 have been identified as amplified, indicating in vivo drug resistance in ovarian cancer. The diagnosis and assessment of amplification levels of certain genes, including PVT1, can be instrumental in predicting poor outcomes and drug resistance in patients with low survival rates. The patent also discusses therapeutics aimed at inhibiting amplification and targeting drug resistance in these patients.
The second patent focuses on Annexin A9 (ANXA9) as a biomarker and therapeutic target in epithelial cancer. The amplification of the ANXA9 gene in the human chromosomal region 1q21 suggests a likelihood of both in vivo drug resistance and metastasis. This gene serves as a crucial biomarker for these disease aspects. The patent outlines the use of interfering RNAs (iRNAs), such as siRNA and miRNA, to inhibit ANXA9 expression, which can be formulated in therapeutic compositions to treat epithelial cancer effectively.
Career Highlights
Wen-Lin Kuo has had a distinguished career, working with prestigious institutions such as the University of California and The University of Texas System. His research has contributed to advancements in understanding cancer biology and developing innovative therapeutic strategies.
Collaborations
Throughout his career, Kuo has collaborated with esteemed colleagues, including Joe W. Gray and Jane Fridlyand. These collaborations have further enriched his research and expanded the impact of his work in the scientific community.
Conclusion
Wen-Lin Kuo's innovative contributions to cancer research, particularly in ovarian cancer, demonstrate his commitment to improving patient outcomes through scientific advancements. His patents reflect a deep understanding of the complexities